meningococcal vaccines

Summary

Summary: Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.

Top Publications

  1. ncbi Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity
    Paul A Kristiansen
    Norwegian Institute of Public Health, University of Oslo, Norway
    Clin Infect Dis 56:354-63. 2013
  2. ncbi Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile
    Ziad A Memish
    National Guard Affairs, King Abdulaziz Medical City, Riyadh, Saudi Arabia
    Pediatr Infect Dis J 30:e56-62. 2011
  3. ncbi Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine
    Cynthia G Whitney
    Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    N Engl J Med 348:1737-46. 2003
  4. ncbi Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    Caroline L Trotter
    Statistics, Economics, and Modelling Department, Health Protection Agency Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Lancet 364:365-7. 2004
  5. ncbi Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity
    Martin C J Maiden
    Dept of Zoology, John Radcliffe Hospital, Oxford University, Oxford, United Kingdom
    J Infect Dis 197:737-43. 2008
  6. ncbi Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults
    Nancy Bermal
    Research Institute for Tropical Medicine, Filinvest Corporate City, Alabang, Muntinlupa City, Philippines
    Hum Vaccin 7:239-47. 2011
  7. pmc A universal vaccine for serogroup B meningococcus
    Marzia M Giuliani
    Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 103:10834-9. 2006
  8. pmc The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance
    Guillermo Madico
    Section of Infectious Diseases, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 177:501-10. 2006
  9. ncbi A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression
    P B Keiser
    Walter Reed Army Institute of Research WRAIR, Silver Spring, MD, USA
    Vaccine 29:1413-20. 2011
  10. ncbi A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
    M Knuf
    Zentrum für Kinder und Jugendmedizin, Johannes Gutenberg University, Germany
    Vaccine 28:744-53. 2010

Detail Information

Publications261 found, 100 shown here

  1. ncbi Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity
    Paul A Kristiansen
    Norwegian Institute of Public Health, University of Oslo, Norway
    Clin Infect Dis 56:354-63. 2013
    ..It is not known whether MenAfriVac has an impact on NmA carriage...
  2. ncbi Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile
    Ziad A Memish
    National Guard Affairs, King Abdulaziz Medical City, Riyadh, Saudi Arabia
    Pediatr Infect Dis J 30:e56-62. 2011
    ....
  3. ncbi Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine
    Cynthia G Whitney
    Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    N Engl J Med 348:1737-46. 2003
    ..In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children...
  4. ncbi Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    Caroline L Trotter
    Statistics, Economics, and Modelling Department, Health Protection Agency Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Lancet 364:365-7. 2004
    ..The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained...
  5. ncbi Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity
    Martin C J Maiden
    Dept of Zoology, John Radcliffe Hospital, Oxford University, Oxford, United Kingdom
    J Infect Dis 197:737-43. 2008
    ..The impact of this intervention on asymptomatic carriage of meningococci was investigated to establish whether serogroup replacement or protection by herd immunity occurred...
  6. ncbi Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults
    Nancy Bermal
    Research Institute for Tropical Medicine, Filinvest Corporate City, Alabang, Muntinlupa City, Philippines
    Hum Vaccin 7:239-47. 2011
    ..The results of this study indicate that ACWY-TT could be used as a third conjugate vaccine in the protection of adolescents against meningococcal disease...
  7. pmc A universal vaccine for serogroup B meningococcus
    Marzia M Giuliani
    Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 103:10834-9. 2006
    ..The strain coverage could be increased to 90% and above by the addition of CpG oligonucleotides or by using MF59 as adjuvant. The vaccine has the potential to conquer one of the most devastating diseases of childhood...
  8. pmc The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance
    Guillermo Madico
    Section of Infectious Diseases, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 177:501-10. 2006
    ..These data provide further support for inclusion of this molecule in a meningococcal vaccine. To reflect the critical function of this molecule, we suggest calling it fH-binding protein...
  9. ncbi A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression
    P B Keiser
    Walter Reed Army Institute of Research WRAIR, Silver Spring, MD, USA
    Vaccine 29:1413-20. 2011
    ..Depletion assays show contributions to bactericidal activity from antibodies to lipooligosaccharide (LOS), fHbp v.1 and OpcA...
  10. ncbi A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
    M Knuf
    Zentrum für Kinder und Jugendmedizin, Johannes Gutenberg University, Germany
    Vaccine 28:744-53. 2010
    ..The safety profile was comparable to licensed controls. The new ACWY-TT conjugate vaccine promises high seroprotection levels against meningococcal disease from 1 year of age...
  11. ncbi Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Vaccine 29:4274-84. 2011
    ..ACWY-TT can be co-administered with MMRV without affecting immunogenicity or safety profiles of either vaccine. This study has been registered at www.clinicaltrials.gov NCT00474266...
  12. pmc Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
    Caroline L Trotter
    Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, UK
    Expert Rev Vaccines 8:851-61. 2009
    ..The magnitude of the herd effects following MCC vaccination was largely unanticipated, and has important consequences for the design and evaluation of new meningococcal vaccines.
  13. ncbi Efficacy of a pneumococcal conjugate vaccine against acute otitis media
    J Eskola
    National Public Health Institute, Helsinki, Finland
    N Engl J Med 344:403-9. 2001
    ..CONCLUSIONS: The heptavalent pneumococcal polysaccharide-CRM197 conjugate vaccine is safe and efficacious in the prevention of acute otitis media caused by the serotypes included in the vaccine...
  14. ncbi Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans
    Samba O Sow
    Centre pour le Développement des Vaccins, Bamako, Mali
    N Engl J Med 364:2293-304. 2011
    ..Group A meningococci are the source of major epidemics of meningitis in Africa. An affordable, highly immunogenic meningococcal A conjugate vaccine is needed...
  15. ncbi The Meningitis Vaccine Project
    F Marc LaForce
    The Meningitis Vaccine Project, PATH, 13 Chemin du Levant, 01210 Ferney Voltaire, France
    Vaccine 25:A97-100. 2007
    ..epidemics in Africa through the development, licensure, introduction, and widespread use of conjugate meningococcal vaccines. Since group A Neisseria meningitidis (N...
  16. ncbi An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children
    Markus Knuf
    Pediatrics Infectious Diseases, University Medicine, Mainz, Germany
    Vaccine 29:4264-73. 2011
    ..ACWY-TT and DTaP-HBV-IPV/Hib co-administration during the second year would facilitate introduction of ACWY-TT into routine toddler vaccination schedules...
  17. ncbi Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents
    Harry Keyserling
    School of Medicine, Emory University, 2015 Uppergate Drive NE, Atlanta, GA 30322, USA
    Arch Pediatr Adolesc Med 159:907-13. 2005
    ..The objective of this study was to compare the tolerability, immunogenicity, and immune memory of MCV-4 with those of a quadrivalent polysaccharide vaccine (PSV-4; Menomune A/C/Y/W-135; Sanofi Pasteur Inc)...
  18. ncbi Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants
    Peter van der Ley
    Unit Vaccinology, National Institute of Public Health and the Environment RIVM, Bilthoven, The Netherlands
    Hum Vaccin 7:886-90. 2011
    ..Several groups have now started the development of native OMV vaccines based on non-toxic LPS mutants, and this Commentary provides an overview of the various approaches and results thus far...
  19. ncbi Long-term protection in children with meningococcal C conjugate vaccination: lessons learned
    Ray Borrow
    Vaccine Evaluation Unit, NW Regional HPA Laboratory, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Expert Rev Vaccines 5:851-7. 2006
    ..The assumption that immune memory was predictive of long-term protection is incorrect, at least after vaccination in infancy. Persistence of antibody and herd immunity may be more relevant for long-term disease control...
  20. pmc Vaccine potential of the Neisseria meningitidis 2086 lipoprotein
    Leah D Fletcher
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    Infect Immun 72:2088-100. 2004
    ..The rLP2086 family of antigens are candidates worthy of further vaccine development...
  21. ncbi Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age
    Roger Baxter
    Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 30:e41-8. 2011
    ..An investigational quadrivalent Neisseria meningitidis serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) has been developed to expand available options for vaccination against invasive meningococcal disease...
  22. ncbi Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, UK
    Clin Infect Dis 51:1127-37. 2010
    ..7-2,4). In this trial, we assessed the immunogenicity of these formulations in infants, who are at greatest risk of contracting MenB disease...
  23. ncbi Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years
    Lars Ostergaard
    Department of Infectious Diseases, Aarhus University Hospital, Denmark
    Vaccine 27:161-8. 2009
    ..Our results present five investigational MenACWY-TT conjugate vaccine formulations which are well tolerated and highly immunogenic in adolescents...
  24. ncbi Global epidemiology of meningococcal disease and vaccine efficacy
    Andrew J Pollard
    University of Oxford, John Radcliffe Hospital, Oxford, England
    Pediatr Infect Dis J 23:S274-9. 2004
    ..Comprehensive disease control can be achieved only with the use of vaccines that target all of these disease-causing serogroups...
  25. ncbi Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
    Steven B Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 21:810-5. 2002
    ..To determine the effectiveness of the Wyeth heptavalent pneumococcal conjugate vaccine against clinical and radiograph-confirmed pneumonia in children...
  26. pmc Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination
    Makda Fisseha
    The Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, Maryland 20910 7500, USA
    Infect Immun 73:4070-80. 2005
    ..However, immunogenicity could be largely restored by use of an adjuvant. These results provide evidence that NOMV from deltalpxL2 mutant strains will be safe and immunogenic in humans when given parenterally...
  27. ncbi Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data
    Ryan T Novak
    Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
    Lancet Infect Dis 12:757-64. 2012
    ..We analysed national surveillance data around PsA-TT introduction to investigate the early effect of the vaccine on meningitis incidence and epidemics...
  28. ncbi Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience
    Mamoudou H Djingarey
    WHO Intercountry Support Team, Ouagadougou, Burkina Faso
    Vaccine 30:B40-5. 2012
    ..The Burkina Faso success augurs well for further rollout of the Men A conjugate vaccine in meningitis belt countries...
  29. ncbi Conquering the meningococcus
    David S Stephens
    Emory University School of Medicine, Atlanta, GA, USA
    FEMS Microbiol Rev 31:3-14. 2007
    ..This report reviews new discoveries impacting prevention and future prospects for conquering the meningococcus as a human pathogen...
  30. ncbi Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial
    Nicoletta Gossger
    Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre and Department of Paediatrics, University of Oxford, Oxford, United Kingdom
    JAMA 307:573-82. 2012
    ..In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a major cause of invasive disease in early childhood in developed countries...
  31. pmc Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines
    John Donnelly
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 107:19490-5. 2010
    ..This assay allows typing of large panels of strains and prediction of coverage of protein-based meningococcal vaccines. Similar assays may be used for protein-based vaccines against other bacteria.
  32. ncbi Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
    María Elena Santolaya
    Departamento de Pediatria, Hospital Dr Luis Calvo Mackenna, Facultad de Medicina, Universidad de Chile, Santiago, Chile
    Lancet 379:617-24. 2012
    ..We assessed immunogenicity and tolerability of a four-component vaccine (4CMenB) in adolescents...
  33. ncbi Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process
    Bas van de Waterbeemd
    Netherlands Vaccine Institute, Unit Research and Development, The Netherlands
    Vaccine 28:4810-6. 2010
    ..With comparable toxicity and yield, no aggregation and cross-protection against other PorA subtypes, these OMV vaccines are potentially safe and effective for parenteral use in humans...
  34. ncbi Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
    Xilian Bai
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Expert Opin Biol Ther 11:969-85. 2011
    ..The novel vaccine Bexsero (previously 4CMenB) has been developed and proven safe and immunogenic in clinical trials...
  35. pmc Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia
    Hani Jokhdar
    School of Epidemiology and Health Science, Medical School, The University of Manchester, Manchester M13 9PT, United Kingdom
    Clin Diagn Lab Immunol 11:83-8. 2004
    ....
  36. ncbi Serogroup B meningococcal vaccines-an unfinished story
    Manish Sadarangani
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
    Lancet Infect Dis 10:112-24. 2010
    ..Vaccines based on subcapsular antigens have recently produced promising results in early clinical trials, and the disease burden might be substantially reduced over the next few years...
  37. pmc Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine
    Richarda M de Voer
    Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    PLoS ONE 5:e12144. 2010
    ..A catch-up campaign was performed targeting all individuals aged 14 months to 18 years. We determined the MenC-specific immunity before and after introduction of the MenC conjugate (MenCC) vaccine...
  38. pmc Prospects for vaccine prevention of meningococcal infection
    Lee H Harrison
    Infectious Diseases Epidemiology Research Unit, 521 Parran Hall, 130 DeSoto St, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Clin Microbiol Rev 19:142-64. 2006
    ..This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine...
  39. ncbi Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
    Han Qing Jiang
    Pfizer Vaccine Research, 401N Middletown Rd, Pearl River, NY 10965, USA
    Vaccine 28:6086-93. 2010
    ..Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed...
  40. ncbi Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
    E Miller
    Immunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, 61 Colindale Avenue, NW9 5EQ, London, UK
    Vaccine 20:S58-67. 2001
    ..Surveillance of the prevalent serogroups and serosubtypes among invasive case isolates has shown no evidence of any capsular switching to serogroup B during the first 18 months of the MCC vaccination programme...
  41. ncbi Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Oleg O Bilukha
    Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC, 1600 Clifton Road NE, MS C 09, Atlanta, GA 30333, USA
    MMWR Recomm Rep 54:1-21. 2005
    ..It also provides updated recommendations regarding use of the tetravalent meningococcal polysaccharide vaccine (MPSV4) and on antimicrobial chemoprophylaxis...
  42. ncbi A surveillance network for meningococcal disease in Europe
    Caroline L Trotter
    Immunization Department, Health Protection Agency Centre for Infections, London, UK
    FEMS Microbiol Rev 31:27-36. 2007
    ..The importance of close collaboration between networks of epidemiologists, microbiologists, and the wider scientific and public health community is demonstrated...
  43. pmc Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine
    Paul A Kristiansen
    Norwegian Institute of Public Health, Nydalen, 0403 Oslo, Norway
    Clin Vaccine Immunol 18:435-43. 2011
    ..5-1,2-2/F5-8, belonging to the ST-23 complex (47%). All serogroup A isolates were ST-2859 of the ST-5 complex with P1.20,9/F3-1. This study forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroup A carriage...
  44. ncbi Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis
    Johan Holst
    Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, P O Box 4404 Nydalen, Oslo NO 0403, Norway
    Vaccine 27:B3-12. 2009
    ..The desire to have a global vaccine strategy that enables susceptible individuals to be protected against all the relevant serogroups of meningococcal disease may become a reality...
  45. pmc Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
    Nick Andrews
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ, United Kingdom
    Clin Diagn Lab Immunol 10:780-6. 2003
    ....
  46. ncbi Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis
    Ellen Murphy
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    J Infect Dis 200:379-89. 2009
    ..We report an extensive survey and phylogenetic analysis of the diversity of fhbp genes and predicted protein sequences in invasive clinical isolates obtained in the period 2000-2006...
  47. ncbi Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age
    S Black
    Center for Global Child Health, Cincinnati Children s Hospital, Cincinnati, Ohio, USA
    Vaccine 28:657-63. 2010
    ..Both vaccines were well tolerated. In children 2-10 years of age, MenACWY-CRM induced a higher immune response than that of MPSV4, and was well tolerated...
  48. pmc Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, P O Box 209, Floor 2, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester M139WZ, United Kingdom
    Clin Vaccine Immunol 17:919-29. 2010
    ..On the basis of genotypic data and predicted immunological cross-reactivity, the potential level of rMenB-OMV vaccine coverage in England and Wales ranges from 66% to 100%...
  49. pmc Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Clin Vaccine Immunol 17:840-7. 2010
    ..Modeling suggested that protection against carriage persists for at least 3 years and predicted the stabilization of serogroup C disease at low levels (fewer than 50 cases per year) up to 2015-2016...
  50. pmc Review of meningococcal group B vaccines
    Dan M Granoff
    Center for Immunobiology and Vaccine Development, Children s Hospital Oakland Research Institute, Oakland, California, USA
    Clin Infect Dis 50:S54-65. 2010
    ..Thus, the prospects have never been better for developing vaccines for prevention of meningococcal disease, including that caused by group B strains...
  51. ncbi Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine
    Sharon H Wong
    The University of Auckland, Auckland, New Zealand
    Pediatr Infect Dis J 28:385-90. 2009
    ..An outer membrane vesicle meningococcal vaccine (MeNZB), was developed for the New Zealand epidemic strain of Neisseria meningitidis B:4:P1.7-2,4...
  52. ncbi Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005
    R Borrow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Vaccine 24:5093-107. 2006
  53. ncbi From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012
    Saverio Caini
    European Programme for Intervention Epidemiology Training EPIET, European Centre for Disease Prevention and Control ECDC, Stockholm, Sweden
    Vaccine 31:1597-603. 2013
    ..Priorities for the future should include incorporating meningitis A vaccination into the existing immunization schedule and assessing its impact at a population level...
  54. ncbi Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease
    Jane O'Hallahan
    Ministry of Health, Wellington, New Zealand
    N Z Med J 122:48-59. 2009
    ..This paper summarises the outcomes of this campaign including coverage levels achieved, evidence of vaccine effectiveness and safety, and the strategies used to manage key events and risks that emerged during the campaign...
  55. ncbi Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004
    Susan S Huang
    Channing Laboratory, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Pediatrics 116:e408-13. 2005
    ..Analysis of colonizing serotypes among healthy children in the community provides critical data on such changes...
  56. pmc Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis
    David S Stephens
    Emory University, Robert W Woodruff Health Sciences Center, 1440 Clifton Road, NE, Atlanta, GA 30322, USA
    Vaccine 27:B71-7. 2009
    ..We review the general status of our knowledge of pathogenesis of meningococcal carriage, transmission and virulence behavior with particular emphasis on the relevance of research on this topic to vaccine development...
  57. ncbi Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign
    C L Trotter
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ
    Commun Dis Public Health 5:220-5. 2002
    ....
  58. ncbi Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso
    Josef Decosas
    Plan International, Accra, Ghana
    Lancet Infect Dis 2:763-5. 2002
    ..Vaccine against the W135 serogroup is expensive and in short supply. Strategies to react to a future African epidemic of W135 meningococcal meningitis with a sufficient and affordable supply of vaccine must be put into place now...
  59. pmc NadA, a novel vaccine candidate of Neisseria meningitidis
    Maurizio Comanducci
    Immunological Research Institute Siena, Chiron S p A, Via Fiorentina 1, 53100 Siena, Italy
    J Exp Med 195:1445-54. 2002
    ..NadA induces strong bactericidal antibodies and is protective in the infant rat model suggesting that this protein may represent a novel antigen for a vaccine able to control meningococcal disease caused by three hypervirulent lineages...
  60. ncbi Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM)
    Carl E Frasch
    Frasch Biologics Consulting, Martinsburg, West Virginia, USA
    Hum Vaccin Immunother 8:715-24. 2012
    ..We summarize the laboratory and clinical studies leading to prequalification of MenAfriVac(TM). The 2011 epidemic season ended with no reported case of group A meningitis in vaccinated individuals...
  61. ncbi Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines
    Jan Poolman
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Expert Rev Vaccines 10:307-22. 2011
    ..These data have implications for the development of new multivalent vaccines...
  62. ncbi Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand
    Richard Arnold
    School of Mathematics, Statistics and Operations Research, Victoria University of Wellington, PO Box 600, Wellington 6140, New Zealand
    Vaccine 29:7100-6. 2011
    ..Between July 2004 and December 2008 an estimated 210 epidemic strain cases (95% CI 100-380), six deaths and 15-30 cases of severe sequelae were avoided in New Zealand due to the introduction of the MeNZB vaccine...
  63. ncbi Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years
    Yvonne Galloway
    Ministry of Health, Wellington, New Zealand
    Int J Epidemiol 38:413-8. 2009
    ..In July 2004 a strain-specific vaccine was introduced to combat an epidemic of group B meningococcal disease in New Zealand. We estimated the effectiveness of this vaccine in pre-school-aged children...
  64. pmc Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands
    Patricia Kaaijk
    National Institute for Public Health and the Environment RIVM, Centre for Infectious Diseases Control Netherlands, Section Vaccinology, Bilthoven, The Netherlands
    BMC Infect Dis 12:35. 2012
    ..Countries that have implemented the MenC vaccine since then in their national immunisation programmes use different schedules. Nevertheless, all involved countries seem to experience substantial declines in the incidence of MenC disease...
  65. pmc Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2
    Oliver Koeberling
    Novartis Vaccines, Siena, Italy
    Clin Vaccine Immunol 16:156-62. 2009
    ..Thus, native OMV vaccines from mutants expressing fHbp variants have the potential to be safe for humans and to confer broad protection against meningococcal disease from strains expressing fHbp from each of the antigenic variant groups...
  66. pmc Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era
    Caroline L Trotter
    Department of Social Medicine, University of Bristol, Bristol, UK
    Clin Vaccine Immunol 15:1694-8. 2008
    ....
  67. ncbi Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults
    David Goldblatt
    Immunobiology Unit, Institute of Child Health, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London, United Kingdom
    J Infect Dis 185:397-400. 2002
    ....
  68. pmc Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines
    Peter T Beernink
    Center for Immunobiology and Vaccine Development, Children s Hospital Oakland Research Institute, Oakland, California, USA
    Infect Immun 76:2568-75. 2008
    ....
  69. ncbi CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells
    Dominic F Kelly
    Department of Paediatrics, University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Blood 108:2642-7. 2006
    ..Detection of peripheral blood memory B-cell responses after vaccination may be a useful signature of successful induction of immunologic memory during novel vaccine evaluation...
  70. pmc Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom
    Ray Borrow
    PHLS Meningococcal Reference Unit, Withington Hospital, Manchester, United Kingdom
    Infect Immun 71:5549-55. 2003
    ..This study provides the first evidence that the number of doses of MCC-TT used in infant immunization schedules could be decreased...
  71. ncbi Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution
    F Marc LaForce
    PATH, 13 Chemin du Levant, Ferney Voltaire 01210, France
    Vaccine 27:B13-9. 2009
    ..Widespread use of such a vaccine is likely to generate herd immunity and to put an end to Group A meningococcal epidemics...
  72. pmc Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra
    Keith S Reisinger
    Primary Physicians Research, Pittsburgh, PA 15241, USA
    Clin Vaccine Immunol 16:1810-5. 2009
    ..MenACWY-CRM is well tolerated in adults 19 to 55 years of age, with immune responses to each of the serogroups noninferior and, in some cases, statistically superior to those to Menactra...
  73. ncbi Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents
    Lisa A Jackson
    Group Health Center for Health Studies, Seattle, Washington 98101, USA
    Clin Infect Dis 49:e1-10. 2009
    ..This study compares the safety and immunogenicity of the Novartis Vaccines investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, with the licensed meningococcal conjugate vaccine, Menactra...
  74. ncbi W135 meningococcal carriage in association with the Hajj pilgrimage 2001: the Singapore experience
    Annelies Wilder-Smith
    Department of Infectious Diseases, Travellers Health and Vaccination Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore
    Int J Antimicrob Agents 21:112-5. 2003
    ..These findings would support a policy of eradication of pharyngeal carriage in returning pilgrims to prevent introduction and dissemination of meningococci...
  75. ncbi Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial
    K P Perrett
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Australia
    Clin Infect Dis 50:1601-10. 2010
    ..The response to a Haemophilus influenzae type b-MenC conjugate (Hib-MenC) booster was also measured...
  76. ncbi Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
    Carl E Frasch
    Frasch Biologics Consulting, PO Box 986, Martinsburg, WV, USA 25402
    Vaccine 27:B112-6. 2009
    ..3) Meningococcal polysaccharide, polysaccharide-protein conjugates, and outer membrane vesicle vaccines all induce SBA shown to be effective in direct proportion to the percent of vaccinees with SBA activity...
  77. ncbi Neisseria meningitidis B vaccines
    Donatella Panatto
    Department of Health Sciences, University of Genoa, Via Pastore 1, 16132, Genoa, Italy
    Expert Rev Vaccines 10:1337-51. 2011
    ..The aims of this article are to describe the most recent developments in meningococcal B vaccines and to discuss how these vaccines can contribute to containing meningococcal disease...
  78. pmc The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB
    D R Martin
    Insitute of Environmental Science and Research ESR, Porirua, New Zealand
    Clin Vaccine Immunol 13:486-91. 2006
    ..4 epitope of the PorA protein supports the public health decision to use a strain-specific vaccine for the control of New Zealand's epidemic of meningococcal disease...
  79. pmc NadA diversity and carriage in Neisseria meningitidis
    Maurizio Comanducci
    IRIS, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Infect Immun 72:4217-23. 2004
    ..The presence of NadA can therefore be used as a tool to study the dynamics of meningococcal infections and understand why this bacterium, which is mostly a commensal, can become a severe pathogen...
  80. ncbi A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt
    Judith E Mueller
    Agence de Medecine Preventive, Institut Pasteur, 25 28 Rue du Dr Roux, 75724 Paris Cedex 15, France
    Int J Infect Dis 14:e553-9. 2010
    ..Epidemic waves occur if new meningococcal strains which escape pre-existing immunity, enter the population. Future research should include the impact of viral co-infection on bacterial colonization and invasion...
  81. pmc The modular architecture of meningococcal factor H-binding protein
    Peter T Beernink
    Center for Immunobiology and Vaccine Development, Children s Hospital Oakland Research Institute, Oakland, CA 94609, USA
    Microbiology 155:2873-83. 2009
    ..Collectively, the data suggest that recombination between Neisseria meningitidis and N. gonorrhoeae progenitors generated a family of modular, antigenically diverse meningococcal fHbps...
  82. ncbi Meningococcal C conjugate vaccine: the experience in England and Wales
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 27:B20-9. 2009
    ..The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years...
  83. pmc Variation of the factor H-binding protein of Neisseria meningitidis
    Carina Brehony
    Department of Zoology, University of Oxford, OX1 3PS, UK
    Microbiology 155:4155-69. 2009
    ..The highest levels of selection were observed in regions corresponding to epitopes recognized by previously described bactericidal monoclonal antibodies...
  84. ncbi Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
    Cressida Auckland
    Immunisation Department, Centre for Infections, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
    J Infect Dis 194:1745-52. 2006
    ..The meningococcal serogroup C conjugate (MCC) vaccine was introduced into the United Kingdom with licensure based on immunogenicity data not efficacy data...
  85. ncbi A review of vaccine research and development: meningococcal disease
    Marc P Girard
    University Paris 7, 39 rue Seignemartin, FR 69008 Lyon, France
    Vaccine 24:4692-700. 2006
    ..However, effective global prevention of meningococcal disease will not be achievable without the development of a vaccine against Group B meningitis, for which outer membrane protein vaccines are under development...
  86. ncbi Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain
    Amparo Larrauri
    Red Nacional de Vigilancia Epidemiológica, Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Sinesio Delgado 6, 28029 Madrid, Spain
    Vaccine 23:4097-100. 2005
    ..Accordingly, there is a need for ongoing re-evaluation of VE and ascertainment of long-term vaccine protection. The findings reported would allow to decide on the advisability of revising current vaccination guidelines...
  87. pmc Epidemiological profile of meningococcal disease in the United States
    Lee H Harrison
    University of Pittsburgh Graduate School of Public Health and School of Medicine, Pennsylvania, USA
    Clin Infect Dis 50:S37-44. 2010
    ..No vaccine is available for endemic disease caused by serogroup B strains. Two tetravalent (A/C/Y/W-135) meningococcal vaccines are licensed in the United States: a purified polysaccharide product and a polysaccharide-protein ..
  88. pmc Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection
    R Borrow
    PHLS Meningococcal Reference Unit, Withington Hospital, Manchester M20 2LR, London NW9 5EQ, United Kingdom
    Infect Immun 69:1568-73. 2001
    ..These results indicated that the majority of toddlers with an rSBA titer between 8 and 64, and some of those with an hSBA result of <4, have mounted a protective immune response with the induction of immunological memory...
  89. ncbi Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial
    Matthew D Snape
    Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom
    Pediatr Infect Dis J 29:e71-9. 2010
    ....
  90. pmc Risk and protective factors for meningococcal disease in adolescents: matched cohort study
    Joanna Tully
    Academic Centre for Child Health, Queen Mary s School of Medicine and Dentistry at Barts and The London, University of London, London E1 1BB
    BMJ 332:445-50. 2006
    ..To examine biological and social risk factors for meningococcal disease in adolescents...
  91. ncbi Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine
    Jo Anne Welsch
    Children s Hospital Oakland Research Institute, Oakland, CA 94609, USA
    J Immunol 172:5606-15. 2004
    ..meningitidis strains expressing GNA1870 subvariant 1 proteins. The data support GNA1870 as a promising vaccine candidate for prevention of meningococcal group B disease caused by GNA1870 variant 1 strains...
  92. pmc Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086
    Alessandro Mascioni
    Wyeth Research, Structural Biology and Computational Chemistry, Cambridge, Massachusetts 02140 and Wyeth Vaccines Research, Pearl River, New York 10965, USA
    J Biol Chem 284:8738-46. 2009
    ..A surface of subfamily-defining residues was identified on one face of the protein, offering an explanation for the induction of subfamily-specific bactericidal antibodies...
  93. ncbi Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
    Matthew D Snape
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LJ, United Kingdom
    Clin Infect Dis 43:1387-94. 2006
    ....
  94. ncbi Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci
    Stephanie Dellicour
    Liverpool School of Tropical Medicine, Liverpool, UK
    Trop Med Int Health 12:1409-21. 2007
    To investigate the effect of meningococcal vaccines on pharyngeal carriage of meningococci.
  95. ncbi Meningococcal carriage in the African meningitis belt
    Caroline L Trotter
    Department of Social Medicine, University of Bristol, Bristol, UK
    Lancet Infect Dis 7:797-803. 2007
    ..Carefully designed carriage studies are needed to measure and interpret the impact of meningococcal group A conjugate vaccines in Africa...
  96. pmc Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, P O Box 209, Floor 2, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WZ, United Kingdom
    J Clin Microbiol 47:3577-85. 2009
    ..Expression studies and serum bactericidal antibody assays will serve to enhance predictions of coverage and will augment ongoing studies regarding the significance of IS1301 within the ST269 cluster...
  97. ncbi Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries
    Luis Jodar
    WHO, Geneva, Switzerland
    Lancet 361:1902-4. 2003
  98. pmc Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
    Mary E Ramsay
    Public Health Laboratory Service Communicable Disease Surveillance Centre, London, NW9 5EQ
    BMJ 326:365-6. 2003
  99. ncbi Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate v
    Terhi Kilpi
    National Public Health Institute KTL, Helsinki, Finland
    Clin Infect Dis 37:1155-64. 2003
    ..The 2 boosters seemed to provide equal protection against AOM, but PncPS induced markedly higher antibody concentrations. The efficacy of PncOMPC was comparable to that of the recently licensed pneumococcal conjugate vaccine...
  100. ncbi New vaccines require potent adjuvants like AFPL1 and AFCo1
    O Perez
    Immunology Department, Finlay Institute, Havana City, Cuba
    Scand J Immunol 66:271-7. 2007
    ..Both are very promising adjuvants...
  101. ncbi Impact of meningococcal C conjugate vaccine in the UK
    P Balmer
    Meningococcal Reference Unit, Manchester PHL, Withington Hospital
    J Med Microbiol 51:717-22. 2002
    ..Surveillance of the genotypic and phenotypic characteristics of invasive and carriage isolates has shown no evidence to date of capsular switching from serogroup C to serogroup B...

Research Grants42

  1. An engineered meningococcal OMV vaccine for Africa against all capsular groups
    Dan M Granoff; Fiscal Year: 2013
    ....
  2. EMERGING INFECTIONS PROGRAM
    Timothy F Jones; Fiscal Year: 2011
    ..abstract_text> ..
  3. Evaluation of vaccination reminder/recall systems for adolescent patients
    Peter Szilagyi; Fiscal Year: 2009
    ..This study evaluates the effectiveness of patient reminder/recall in improving both adolescent immunization delivery and the delivery of other critical adolescent preventive services. ..
  4. PROPHOLAXIS OF H. INFLUENZAE AND OTHER INFECTIONS
    Mathuram Santosham; Fiscal Year: 1991
    ..BPIG is prepared from the pooled plasma of adult donors immunized with Hib, pneumococcal and meningococcal vaccines. Between June 1983 and April 1986, infants were randomized in a double-blind fashion to receive BPIG (n=..
  5. Prevention of group B Neisseria meningitidis Infection
    RANDALL MRSNY; Fiscal Year: 2004
    ..The proposed studies will combine immunological and genetic approaches with a novel vaccine platform to select one or two lead candidates for further development. ..
  6. Neisseria meningitidis antigens expressed in infection
    Dan Granoff; Fiscal Year: 2005
    ..meningitidis disease, including group B strains for which there is currently no vaccine available. Also, characterization of gene expression in an in vivo model will lead to a better understanding of meningococcal pathogenesis. ..
  7. Molecular basis meningococcal group A capsular immunity
    Dan Granoff; Fiscal Year: 2007
    ..abstract_text> ..
  8. Molecular bssis of mef-mediated antibiotic resistance in Streptococcus pneumoniae
    David S Stephens; Fiscal Year: 2010
    ..pneumoniae. ..
  9. Center for Clinical and Translational Science Advancement at Emory
    David Stephens; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  10. CLINICAL RESEARCH CURRICULUM AWARD
    David Stephens; Fiscal Year: 2004
    ..abstract_text> ..
  11. MENINGOCOCCAL LIPOOLIGOSACCHARIDE & MUCOSAL PATHOGENESIS
    David Stephens; Fiscal Year: 2007
    ..Meningococcal infections remain devastating in the United States and worldwide. Current meningococcal vaccines have major limitations and antibiotic-resistant meningococci are emerging, emphasizing the need to better ..
  12. Regulation of Capsule Biosynthesis in N. meningitidis
    David Stephens; Fiscal Year: 2006
    ..protein, appears conserved, is essential for capsule expression and is a candidate for conjugate or other meningococcal vaccines that prevent disease due to all invasive serogroups...
  13. Forensic Detection of Salmonella Resistance and Subtype
    Lee Harrison; Fiscal Year: 2005
    ..enterica and 2) molecular methods for rapid outbreak detection among S. enterica serovars. ..
  14. Unique Neisseria Meningitidis B Capsular Epitopes
    GREGORY MOE; Fiscal Year: 2009
    ..Thus, this proposal offers a novel approach to develop a protective PS-based vaccine that avoids safety concerns of eliciting autoantibodies and for understanding structural differences between group B capsular and host PSA antigens. ..
  15. MIMETICS OF CAPSULAR EPITOPES OF NEISSERIA MENINGITIDIS
    GREGORY MOE; Fiscal Year: 2004
    ..The results also may identify new candidate molecules for inclusion in a future vaccine for prevention of NmB disease. ..
  16. Using MEPS Data to Inform Public-Plan Consumerism
    Matthew Davis; Fiscal Year: 2007
    ..Findings will have immediate relevance for implementation of the HOA projects and other consumerism efforts. [unreadable] [unreadable] [unreadable]..
  17. New Paradigms of Cerebral Palsy Etiology: A Comprehensive Case Control Study
    NIGEL SEFTON PANETH; Fiscal Year: 2010
    ..Maternal interviews and birth certificates will inform the above analyses by linking molecular information to self-reported and recorded clinical events and conditions. ..
  18. Oxygen and Phototherapy in perinatal period: Risk of Acute Lymphoctyic Leukemia
    Nigel Paneth; Fiscal Year: 2008
    ..If these treatments increase the risk of leukemia, it should be possible to find alternative ways to manage newborn problems that minimize exposure to these treatments [unreadable] [unreadable] [unreadable]..
  19. Activation of human TLR4 by endotoxin binding to MD-2
    SHANTA ZIMMER; Fiscal Year: 2008
    ..The study of other diseases (e.g. atherosclerosis, inflammatory bowel disease, and asthma) with inflammatory components which are mediated by the activation of TLR4 and MD-2 may also benefit from this work. ..
  20. HPV Outcomes: Prevention Epidemiology and Surveillance (HOPES)
    Cosette Marie Wheeler; Fiscal Year: 2010
    ..Image-based diagnostic standards will be critical to future population evaluations. ..
  21. co-Trimoxazole in Zambian Infants (TZI)
    CHRISTOPHER GILL; Fiscal Year: 2007
    ..abstract_text> ..
  22. IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSE
    Gregory A Poland; Fiscal Year: 2010
    ..The knowledge gained from these studies will enable us to design new strategies and new vaccines to protect human health against viral diseases. ..
  23. Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury
    Alan Cross; Fiscal Year: 2010
    ..Since inhibitors of sialidase are commercially available, these studies will provide the experimental rationale for testing a new therapeutic approach to the treatment of lung injury. ..
  24. RCT to evaluate guidelines for acute rhinosinusitis
    Jane Garbutt; Fiscal Year: 2008
    ..In addition, knowledge gained from this research could be used to decrease the inappropriate use of antibiotics. [unreadable] [unreadable]..
  25. NICHD Institutional Training for Pediatricians
    Kathryn Edwards; Fiscal Year: 2007
    ..3.) Evaluate the success of the training program through both process and outcomes evaluation. (4.) Implement continuous quality improvement procedures that will enhance the PPOR components, curriculum, and overall program. ..
  26. New Methods for Evaluating Interobserver Agreement
    Michael Haber; Fiscal Year: 2006
    ..Existing and new agreement indices will be compared and linked. All the proposed methods will be applied to real data sets from the behavioral and biomedical sciences. [unreadable] [unreadable]..
  27. DETERMINING/UNDERSTANDING BARRIERS TO ADULT IMMUNIZATION
    Richard Zimmerman; Fiscal Year: 2001
    ..This project will furnish relevant, up-to-date to enhance policy planning, practice management and medical education. ..
  28. SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS
    Alan Cross; Fiscal Year: 2002
    ..These studies will define a new mechanism for a rapidly adaptable, temporally- restricted local response to inflammation. This proposal will provide new targets and additional approaches to the treatment of inflammation. ..
  29. Novel Approaches to the Inhibition of Anthrax Toxin
    ANDREW ARTENSTEIN; Fiscal Year: 2003
    ....
  30. Epidemiologic Methods: Resistant Nosocomial Infections
    Marc Lipsitch; Fiscal Year: 2004
    ..This will in turn lead to better practices to reduce the incidence of ARNI. ..
  31. ENHANCING MUCOSAL IMMUNE RESPONSES BY MICROENCAPSULATION
    Paul Offit; Fiscal Year: 2005
    ..The availability of microencapsulated virus provides a unique opportunity to understand the relationship between APC and protective mucosal immune responses. ..
  32. FACTORS IN PEDIATRIC AIDS TRANSMISSION AND PATHOGENESIS
    Stephen Spector; Fiscal Year: 2005
    ..The findings of this research will provide an improved understanding of the pathogenesis of HIV-1 infection of children and perinatal transmission, and help to develop improved treatment/prevention strategies. ..
  33. ADOLESCENT MEDICINE TRIALS UNIT (AMTU)
    Stephen Spector; Fiscal Year: 2005
    ..The experience of our team in HIV care, clinical trials and laboratory studies, we believe, will enable our group to make a significant contribution to the success of the ATN. ..
  34. Pediatric ACTG Coordinating and Operations Center
    Stephen Spector; Fiscal Year: 2005
    ..abstract_text> ..
  35. VACCINE EFFICACY IN CHILDREN WITH SICKLE CELL DISEASE
    Thomas Adamkiewicz; Fiscal Year: 2006
    ..abstract_text> ..
  36. PEDIATRIC AIDS CLINICAL TRIALS GROUP
    Stephen Spector; Fiscal Year: 2006
    ..abstract_text> ..
  37. Early events during infection with anthrax
    Alan Cross; Fiscal Year: 2006
    ..abstract_text> ..
  38. Evaluation of Anti-endotoxin Vaccine for Human Use
    Alan Cross; Fiscal Year: 2006
    ..If successful, these studies will lead to phase II and Ill studies for the prevention and treatment of sepsis. ..
  39. Effect of Neisserial Porin in Immune Cell Apoptosis
    Lee Wetzler; Fiscal Year: 2006
    ..In addition, these results can have significant implications in Neisserial pathogenesis, especially since we have new preliminary data that intact live meningococci can also protect cells from apoptosis. ..
  40. INTERFERON Y MEDIATES ANTI E COLI DEFENSES AND SEPSIS
    Alan Cross; Fiscal Year: 2001
    ..The demonstration of a spectrum of responses to LPS in these studies may identify the earliest changes in cytokine responses that predict the development of sepsis. ..